A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Trial Profile

A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Linsitinib (Primary) ; Bortezomib; Dexamethasone; Erlotinib; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 24 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 05 Feb 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 26 Jan 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top